PowerShares Dynamic Large Cap Growth ETF
CP’s Rail Traffic Growth Was the Lowest among Its Peers
Canadian Pacific Railway (CP) reported 1.5% YoY (year-over-year) total traffic volume growth in Week 49.
Have Bears Strengthened Their Grip on SWK?
SWK’s short interest increased dramatically after its first-quarter earnings.
What Praxair’s Short Interest Suggests before 4Q17 Earnings
The latest short interest data as of December 30, 2017, show that Praxair’s (PX) short interest has increased since its 3Q17 earnings were announced on October 26, 2017.
What Analysts Recommend for Priceline after 3Q17 Results
Of the 31 analysts rating Priceline’s stock after the company’s 3Q17 earnings report, 19.4% (six analysts) have issued a “strong buy” rating and 58.1% (18 analysts) have issued a “buy” rating.
Priceline’s 3Q17 Revenue Defies Tough Conditions
For the third quarter of 2017, Priceline’s (PCLN) revenue rose 20.2% YoY or year-over-year to $4.4 billion, driven by strong gross bookings growth of 19% YoY.
How the Meituan–Dianping Investment Could Help Priceline
On October 19, Priceline (PCLN) announced its $450.0 million investment in China-based Meituan–Dianping.
Why Priceline’s Margin Is on a Downtrend
For 3Q17, Priceline’s management expects its gross profit to increase 15.5%–20.5%.
What’s Priced into Marriott’s Valuation Multiple Now?
Marriott is now trading at a forward EV-to-EBITDA multiple of 15.5x, compared with its average historical valuation of 13.9x since January 2008.
Could Marriott’s Partnership with Alibaba Be a Game Changer?
Marriott (MAR) has entered into a joint venture agreement with China’s Alibaba Group (BABA) with an aim to provide a seamless travel experience in China.
Why Investors Should Pay Attention to Marriott’s Debt Levels
Total debt on Marriott’s balance sheet increased from $3.8 billion at the end of 2014 to $4.1 billion at the end of 2015 and $8.2 billion at the end of 4Q16.
What Should We Make of Priceline’s Increasing Leverage?
Priceline has been funding some of its acquisitions through debt. Total debt on its balance sheet has risen from $3.9 billion at the end of 2014 to 6.2 billion at the end of 2015.
Eli Lilly in 2Q17: Oncology Products Lose Revenues
Alimta sales fell ~12.0% to $532.9 million in 2Q17 compared to $607.1 million in 2Q16.
Bristol-Myers Squibb Reported Revenue Growth in 1Q17
Bristol-Myers Squibb (BMY) reported 12% growth in its top line to ~$4.93 billion during 1Q17 due to 13% operational growth in its revenues
Performance of Eli Lilly’s Endocrine Products in 1Q17
Humalog reported growth of 17% to $708.4 million during 1Q17, compared to $606.3 million for 1Q16.
Eli Lilly & Co.’s Developments in 1Q17
In 1Q17, Eli Lilly and Boehringer Ingelheim launched Synjardy XR tablets in the US for patients with type 2 diabetes.
Exploring Eli Lilly’s Oncology Franchise in 2016
Eli Lilly’s (LLY) Human Pharmaceuticals segment also consists of the oncology franchise. Key drugs in this franchise include Alimta, Erbitux, Cyramza, and Portrazza.
A Look at Opdivo’s Performance in 2016
Bristol-Myers Squibb’s (BMY) latest drug, Opdivo, was the seventh drug to be approved by the FDA for the treatment of melanoma.
Eli Lilly & Co.’s Oncology Franchise
Erbitux’s sales fell 13% to $153.7 million in 4Q16, compared to ~$176.2 million in 4Q15.
Bristol-Myers Squibb’s Strong Oncology Segment
With the strong performance of Opdivo, Bristol-Myers Squibb’s (BMY) oncology segment emerged as its largest revenue contributor in 4Q16.
What to Expect from Eli Lilly’s Oncology Franchise in 4Q16
The oncology franchise contributes around 18% of Lily’s total revenues.
How Did Bristol-Myers Squibb’s Blockbuster Oncology Drug Perform?
Bristol-Myers Squibb’s (BMY) latest drug Opdivo was the seventh drug to be approved by the US FDA for the treatment of melanoma.
How Did Bristol-Myers Squibb’s Oncology Segment Perform in 3Q16?
Due to the strong performance of Opdivo, the oncology segment has emerged as the largest revenue contributor for Bristol-Myers Squibb (BMY) in 3Q16.
What You Should Know about Eli Lilly’s Oncology Franchise
Eli Lilly’s (LLY) Human Pharmaceuticals segment also contains its oncology franchise. Key drugs in this franchise include Alimta, Erbitux, and Cyramza.
Eli Lilly and Co.’s 3Q16 Estimates: Oncology Franchise
Oncology franchise Eli Lilly and Co.’s (LLY) human pharmaceuticals segment also consists of the oncology franchise. The oncology franchise contributes around 18% of total revenues for Lilly. Key drugs in this segment include Alimta, Erbitux, and Cyramza. A new drug, Portrazza, launched in US markets in December 2015. Erbitux Erbitux is a drug used in […]
Roche Goes Up against Bristol-Myers Squibb in Oncology Drug Space
Bristol-Myers Squibb’s (BMY) latest drug, Opdivo ,was the seventh drug to be approved by the FDA for the treatment of melanoma. Opdivo reported revenues of $840 million in 2Q16, as compared to $122 million in 2Q15.
Eli Lilly’s Antidepressant and Schizophrenia Drug Sales Are Down
Another franchise from Eli Lilly’s Human Pharmaceuticals segment is the neuroscience franchise—its drugs include Zyprexa, Cymbalta, and Strattera.
How Will Dollar General’s Stock Price Respond to the Fiscal 2Q16 Results?
Dollar General’s stock price has risen by 23.6% on a YTD basis to $89.49 as of August 16, 2016.
Which Off-Price Retailer Is Operating at the Highest Margins?
Major off-price retailers have strong margins supported by lean operating models, efficient inventory management, and strong vendor relationships.
Cost Savings and Price Increase Helped Clorox’s Margin Growth
Clorox’s (CLX) fiscal year-to-date cash flow generation came in at $0.3 billion, compared to $0.4 billion in the same period in 2015.
Understanding Intuitive Surgical’s Geographical Profile
Intuitive Surgical (ISRG) has established geographical growth as one its major growth drivers after procedure growth.
Estée Lauder’s Makeup Segment Boosted Its Operating Income
Estée Lauder’s makeup segment’s net revenue rose 7.3% in reported terms and 11% in constant currency terms to $1.2 billion in fiscal 3Q16.
How Did the Stock Market React to Dr Pepper Snapple’s 1Q16 Data?
Dr Pepper Snapple’s stock price appreciated by ~3% to $90.38 on April 27, in reaction to the company’s strong 1Q16 results and revised outlook.
EMA Validates Opdivo’s Application for Additional Indications
Opdivo is an oncology drug from Bristol-Myers Squibb that is already approved by the FDA and EMA for the treatment of patients with melanoma. On March 30, EMA validated the type-II variation application for extending the current indications for Opdivo.
Can Off-Price Retailers Sustain Same-Store Sales Growth in 2016?
While department stores like Macy’s struggled to report decent numbers in 2015, off-price retailers have continued to display their strength.
A Close Look at B&G Foods’ Operating Margins in Fiscal 4Q15
B&G Foods (BGS) reported that operating margin for fiscal 4Q15 rose to 14.2% compared to 12.7% in 4Q14. Operating margin for fiscal 2015 was 17.8% compared to 13.6% in 2014.
TJX Companies’ US Business in Fiscal 4Q16
The US business of TJX Companies consists of 1,156 T.J. Maxx stores, 1,007 Marshalls stores, 526 HomeGoods stores, and eight Sierra Trading Post stores.
Credit Agricole Downgrades Hormel Foods to ‘Underperform’
Hormel Foods Corporation (HRL) has a market cap of $22.7 billion. HRL fell by 3.6% to close at $42.89 per share as of February 18, 2016.
Carnival Sees China as Its Biggest Potential Area of Expansion
Carnival identified China as its biggest potential area of expansion. It announced that Carnival Cruise Line will enter the Chinese market in 2017.
What Caused Carnival Corporation’s Revenue to Fall?
Carnival Corporation (CCL) saw a marginal fall in its top line numbers. The revenues for 4Q15 fell by about 2.5% year-over-year to reach $3.71 billion.
What Was Wall Street Analysts’ View on T-Mobile’s Performance?
The price performance of T-Mobile has been significant in the past 52 weeks as of December 10. During the period, T-Mobile’s price rose by a significant 43.6%.
Assessing Disney’s Business Segment Performance in Fiscal 2015
Disney’s (DIS) Media Networks segment was the biggest contributor to its revenue, at 44% or $52.5 billion, in fiscal 2015.
Understanding the structure of the global power sector
While the power sector differs country by country, the operational structure of the sector across the world is pretty much the same.